REVIEW ARTICLE OF DIABETES MELLITUS

Praveen Kumar Dasari*, P. Karunakar, Kumar Raja Jayavarapu, Ch. Sree Lakshmi Gowthami, K. Myna, S. Vasu, Sk. Naseem

Mother Teresa Pharmacy College, Sathupally, Khammam, Telangana.

ABSTRACT

Diabetes mellitus is a chronic metabolic disorder identify by raised blood glucose levels resulting from faults in insulin secretion, insulin action, or both. It encompasses two main types: Type 1 diabetes (T1D), an autoimmune condition that leads to insulin deficiency, and Type 2 diabetes (T2D), primarily associated with insulin resistance and eventual pancreatic beta-cell dysfunction. The global prevalence of diabetes is rising, making it a major public health concern. This article reviews the pathophysiology, risk factors, diagnostic criteria, and therapeutic approaches for diabetes. Emphasis is placed on advancements in pharmacological treatments, including insulin therapies and newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors, as well as non-pharmacological interventions like lifestyle modifications. Early detection and comprehensive management are crucial to reducing complications, such as cardiovascular disease, neuropathy, and retinopathy. Furthermore, the article discusses the role of technology in diabetes care, including continuous glucose monitoring systems and insulin pumps. Despite significant progress in understanding and treating diabetes, challenges in prevention and treatment adherence remain, necessitating continued research and innovation in both therapeutic and management strategies.

KEYWORDS: Diabetes mellitus, blood glucose, insulin, pharmacotherapy.

INTRODUCTION TO DIABETES

Diabetes mellitus DM is a group of metabolic diseases characterized by chronic hyperglycaemic to defects in insulin secretion, insulin action, or both. It is classified into two

primary types: Type 1 diabetes T1D which is an autoimmune disorder leading to the destruction of insulin-producing beta cells in the pancreas, and Type 2 diabetes T2D which primarily results from insulin resistance combined with an eventual beta-cell dysfunction. Gestational diabetes GDM another form of diabetes, occurs during pregnancy and typically resolves post-delivery but increases the risk of developing T2D later in life.

With the rising global incidence of diabetes, the disease has become a significant public health concern. According to the International Diabetes Federation IDF there are over 460 million people living with diabetes worldwide, with projections estimating this number will exceed 700 million by 2045. Managing diabetes involves a combination of lifestyle modifications, blood glucose monitoring, and pharmacological interventions.

Pathophysiology of Diabetes

In T1D, the immune system mistakenly targets and destroys pancreatic beta cells, leading to an absolute insulin deficiency. This condition necessitates lifelong insulin therapy. On the other hand, T2D is characterized by insulin resistance, where the body's cells fail to respond to insulin properly, causing elevated blood glucose levels. Over time, the pancreas compensates by producing more insulin, but as the disease progresses, beta cells become less efficient, and insulin production declines.

Increased blood glucose levels lead to long-term complications such as cardiovascular diseases, nephropathy, neuropathy, retinopathy, and impaired wound healing. The management of diabetes primarily aims to normalize blood glucose levels to prevent or delay these complications.

Conventional Diabetes Management

The cornerstone of diabetes management remains the regulation of blood glucose levels through lifestyle interventions and pharmacotherapy.

Lifestyle Modifications

Diet: A balanced diet with an emphasis on low glycemic index foods, fiber, and healthy fats is essential. Reducing the intake of refined sugars and carbohydrates can help regulate blood glucose levels.

Exercise: Regular physical activity improves insulin sensitivity and helps in weight management, which is particularly crucial for T2D patients.

Weight Management: Maintaining an ideal body weight is critical for managing blood glucose levels, especially in T2D.

Pharmacological Treatments

Insulin Therapy: In T1D, insulin administration is necessary to compensate for the lack of insulin production. Insulin can also be used in T2D when oral medications are insufficient.

Oral Medications for T2D: Medications like metformin (a biguanide), sulfonylureas, thiazolidinediones, and DPP-4 inhibitors are commonly used to control blood glucose levels in T2D patients.

GLP-1 Agonists and SGLT2 Inhibitors: These newer classes of drugs help in reducing blood glucose levels while also providing cardiovascular benefits and weight loss.

While conventional therapies have significantly improved the prognosis for diabetes patients, they come with side effects, and there is an increasing interest in exploring alternative or complementary treatments, particularly those derived from natural products.

Natural Products in Diabetes Management

The growing interest in natural remedies has led to the exploration of various plant-based compounds that may help manage diabetes. Some of these remedies have shown significant promise in clinical trials.

Bitter Melon (*Momordica charantia*)

Bitter melon contains compounds like charantin and momordicoside, which can stimulate insulin secretion and enhance insulin sensitivity. Several clinical trials suggest its potential in lowering blood glucose levels, especially in T2D patients.

Fenugreek (*Trigonella foenum-graecum*)

Fenugreek seeds are rich in soluble fiber and the amino acid 4-hydroxyisoleucine, which enhances insulin secretion and improves glucose uptake. Studies have shown fenugreek supplementation to reduce blood glucose and improve insulin sensitivity.

Ginseng (*Panax ginseng*)

Ginseng contains active compounds known as ginsenosides, which have been shown to improve insulin sensitivity and reduce oxidative stress. Clinical trials suggest that ginseng may help lower blood glucose levels in T2D patients.

Turmeric (*Curcuma longa*)

Curcumin, the active ingredient in turmeric, has anti-inflammatory and antioxidant effects. Studies indicate that curcumin can reduce insulin resistance, improve glucose metabolism, and protect against diabetes-related complications.

Berberine (from *Berberis* species)

Berberine has gained attention for its anti-diabetic properties, including enhancing insulin sensitivity, decreasing liver glucose production, and increasing glucose uptake by muscle cells. Clinical evidence suggests that berberine can be as effective as metformin in controlling blood glucose levels.

Cinnamon (*Cinnamomum verum*)

Cinnamon contains bioactive compounds like cinnamaldehyde, which can improve insulin sensitivity and mimic the effects of insulin. Cinnamon supplementation has been shown to reduce fasting blood glucose levels and improve lipid profiles.

Aloe Vera (*Aloe barbadensis*)

Aloe vera gel contains compounds like polysaccharides that have anti-diabetic effects. Research has shown that aloe vera may reduce blood glucose levels and protect against complications like neuropathy.

Gymnema Sylvestre

Known as "sugar destroyer" in Ayurvedic medicine, gymnema has compounds that reduce sugar absorption in the intestines and enhance insulin secretion. It has shown promising results in improving blood glucose control and reducing the craving for sweets.

Mechanisms of Action

The anti-diabetic effects of these natural products involve several mechanisms, including:

Improvement of Insulin Sensitivity: Many plants, such as ginseng and fenugreek, enhance insulin sensitivity, allowing cells to respond better to insulin.

Stimulation of Insulin Secretion: Plants like bitter melon and gymnema can stimulate insulin secretion from the pancreas.

Reduction in Hepatic Glucose Production: Compounds such as berberine and cinnamon can reduce glucose production by the liver, which is a major contributor to high blood glucose levels.

Anti-inflammatory and Antioxidant Effects: Chronic inflammation and oxidative stress contribute to insulin resistance and diabetic complications. Plants like turmeric and ginseng reduce these effects and protect against beta-cell dysfunction.

Safety and Side Effects

While many natural remedies are safe, they can interact with conventional diabetes medications, leading to potential side effects such as hypoglycaemia or altered drug metabolism. Bitter melon, for example, may cause hypoglycaemia when taken with other blood glucose-lowering drugs. Berberine can interact with cytochrome P450 enzymes, affecting the metabolism of various medications. Therefore, it is essential to consult healthcare providers before using these natural remedies, especially for patients who are already on prescribed medications.

CONCLUSION

Diabetes mellitus, a complex and increasingly prevalent metabolic disorder, poses significant challenges to global health. Both Type 1 and Type 2 diabetes require comprehensive management strategies to control blood glucose levels and prevent complications. Advances in pharmacological treatments, such as the development of novel medications like GLP-1 receptor agonists and SGLT2 inhibitors, have improved patient outcomes, but the cornerstone of diabetes management remains lifestyle modifications, including diet and exercise. Early diagnosis, personalized care plans, and continuous monitoring are essential to minimizing the risk of long-term complications such as cardiovascular disease, nephropathy, neuropathy, and retinopathy. The integration of technology, including continuous glucose monitoring and insulin pumps, has further transformed diabetes management, enhancing treatment precision and patient quality of life. However, despite these advancements, challenges persist, particularly with regard to prevention, adherence to treatment regimens, and access to healthcare resources. Ongoing research into the pathophysiology, prevention, and

management of diabetes is crucial to addressing these issues, with the goal of ultimately reducing the global burden of this chronic disease.

REFERENCE

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2014; 37: 81-90.

2. American Diabetes Association. Clinical Practice Recommendations. Standards of medical care in diabetes, 2014. Diabetes Care, 2014; 37: 14-80.

3. Mensing C, Boucher J, Cypress M, et al. National standards for diabetes self-management education. Diabetes Care, 2005; 28: 72-79.

4. American Diabetes Association. Clinical Practice Recommendations. Diabetes and driving. Diabetes Care, 2014; 37: 97-103.

5. Smaldone A. Glycemic control and hemoglobinopathy: when A1C may not be reliable. Diabetes Spectrum, 2008; 21(1): 46-49.

6. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care, 2013; 36: 1384-95.

7. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care, 2015; 38(8): 1583-91.

8. Beaser RS. Joslin's Diabetes Deskbook: A Guide for Primary Care Providers. 3rd ed. 2014, Boston, Mass: Joslin Diabetes Center, 2014.

9. Umpierrez GE, ed. Therapy for Diabetes Mellitus and Related Disorders. 6th ed. Alexandria, Virg: American Diabetes Association, 2014.

10. Viswanath K, McGavin DD. Diabetic retinopathy: clinical findings and management. Comm Eye Health, 2003; 16(46): 21-24.

11. Michigan Diabetes Research & Training Center, University of Michigan Health System. How to Use the Michigan Neuropathy Screening Instrument, 2017.

12. Consensus Statement of the American Autonomic Society and the American Academy of Neurology. The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Autonomic Nerv Syst., 1996; 58(1-2): 123-4.

13. American College of Cardiology Foundation and American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol., 2010; 56(25): 50-103.

14. American College of Cardiology and American Heart Association. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol., 2014; 63(25): 2935-59.

15. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol., 2002; 40(8): 1531-40.

16. Fletcher G, Ades P, Kligfield P, et al. Exercise Standards for Testing and Training: A Scientific Statement from the American Heart Association. Circulation, 2013; 128: 894-898.

17. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation, 2014; 130(13): 1110-30.

18. American Diabetes Association. Clinical Practice Recommendations. Standards of medical care in diabetes – 2016. Diabetes Care, 2016; 39: 67.

19. Tuttle KR, Kakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care, 2014; 37(10): 2864-83.

20. Thorn L, Gordin D, Harjutsalo V, et al. The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes. Diabetes Care, 2015; 38: 2128-33.